PRIMARY CARE
Recommendation 1
General lifestyle modifications to reduce inflammation and promote immune health. Disease is chronic and relapsingRecommendation 2
regular follow-up to identify and treat flares is indicated.
Recommendation 1
Current International Study Group criteria requireRecommendation 2
aphthous ulcers at least 3x in 12 months, PLUS two of the followingRecommendation 3
genital ulcers, uveitis or retinal vasculitis, erythema nodosum or skin pustles, positive pathergy test.Recommendation 1
Current International Study Group criteria requireRecommendation 2
aphthous ulcers at least 3x in 12 months, PLUS two of the followingRecommendation 3
genital ulcers, uveitis or retinal vasculitis, erythema nodosum or skin pustles, positive pathergy test.Recommendation 1
Topical corticosteroids can help with oral and genital ulcers. Apremilast is another option for mucocutaneous ulcers. Ocular, vascular, or other systemic symptoms require long-term immunosuppressionRecommendation 2
corticosteroids are first-line to induce remission, and azathioprine is first-line as maintenance therapy. TNF-alpha inhibitors and interferon-alpha may be considered in refractory disease.Recommendation 1
General lifestyle modifications to reduce inflammation and promote immune health. Disease is chronic and relapsingRecommendation 2
regular follow-up to identify and treat flares is indicated.Recommendation 1
RheumatologyRecommendation 2
the American College of Rheumatology has a directory. NYU Langone has a dedicated Behcet Disease Center, (646-501-7400). American Behcet Disease Association offers patient and family support. Patients with ocular symptoms should be followed regularly by an ophthalmologist. . Referral to Medical Genetics Department, if available. Initial virtual care is also available through organizations like TeleRare Health.Recommendation 1
Several clinical trials are recruitingRecommendation 2
currently the majority are outside of the US.Follow to receive regular updates to the latest research development on this disease via email newsletter.